The CAR-TCR industry has started 2021 with a bang! With the 4th CAR-T gaining long-awaited approval, Bristol-Myers Squibb have stepped onto the commercial stage, and the CAR-TCR field continues to boom with excitement as the competition heats up.
The current approved therapies have encountered significant difficulties in the commercial market. Cell Therapies come with a high price tag, little long-term efficacy data, and expensive manufacturing processes. Now, your community must gather to:
- Achieve consistency in manufacturing, focusing on automation, allogeneic platforms, scalability, and engineering techniques
- Demonstrate durable response with enhanced construct design,optimized trial design, and long-term follow-up data
- Overcome solid tumor hurdles with combination strategy, specialized clinical delivery, and next-generation engineering strategies
These challenges require ground-breaking work, from discovery through to commercialization. Join the 6th CAR-TCR Summit to learn from the key opinion leaders, and international innovators of the CAR-TCR community, this September.
See more – https://ter.li/ofwzn3